Olopatadine and mizolastine are more effective than placebo for total symptom scores in chronic urticariaSpecific Antihistamines Show Different Success Rates for Chronic Urticaria

Frontiers in Medicine Published August 15, 2026 Study authors: Zixuan Li, Juan Zhang, Yaqi Zheng, Mingyan Zhang, Wenkang Du, Yajun Zhang, Xiaochao Gao, Qing Zhu, J… DOI ↗ Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Consider olopatadine for total symptom scores and fexofenadine for itching reduction in chronic urticaria.

This network meta-analysis evaluated the efficacy of 10 second-generation H1 antihistamines compared to placebo in patients with chronic urticaria across 54 studies involving 7,290 patients. The analysis focused on total symptom scores, itching scores, and wheal scores as primary and secondary outcomes.

Key findings indicate that olopatadine, mizolastine, bilastine, and levocetirizine were more effective than placebo in reducing total symptom scores. Regarding itching scores, all 10 drugs were superior to placebo, though only fexofenadine achieved statistical significance. For wheal scores, ebastine was significantly more effective than both mizolastine and loratadine.

Safety data indicated no significant differences between any of the drugs and placebo; however, fexofenadine demonstrated the lowest adverse reaction rate. The authors note that these conclusions require validation by further high-quality randomized controlled trials. Clinically, olopatadine may be preferred for total symptoms, while fexofenadine is noted for itching reduction and lower adverse reactions, and ebastine for wheal score reduction.

How this fits prior evidence

This network meta-analysis addresses a gap in comparing multiple second-generation H1 antihistamines for chronic urticaria. It extends the evidence regarding treatment options for this condition, specifically following previous findings that classical TCM formulas may enhance antihistamine efficacy in chronic spontaneous urticaria.

Researchers analyzed data from 54 different studies involving over 7,000 patients with chronic urticaria. They compared 10 different second-generation H1 antihistamines to see how well they managed symptoms like itching and the appearance of skin welts.

The analysis found that while all 10 drugs performed better than a placebo, specific medications showed different strengths. For example, olopatadine, mizolastine, bilastine, and levocetirizine were more effective at reducing overall symptom scores. Fexofenadine was specifically noted for its effectiveness in reducing itching, while ebastine was more effective at reducing wheal scores.

Safety results showed no significant differences between the drugs and a placebo. Fexofenadine had the lowest rate of adverse reactions among those tested. Because this was a network meta-analysis of existing data, the findings are not yet definitive. The researchers noted that these results need to be confirmed by more high-quality trials before they can change standard medical practices.

What this means for you:

Different antihistamines may provide varying levels of relief for itching or skin welts in chronic urticaria patients.

Common questions

Which antihistamine is best for overall symptoms?

The study found that olopatadine, mizolastine, bilastine, and levocetirizine were all more effective than a placebo at reducing total symptom scores. However, because this was a meta-analysis of existing data, these results need to be confirmed by further high-quality trials before they can change how doctors treat patients.

Is there a specific drug that helps with itching?

While all 10 drugs tested were better than a placebo for itching, only fexofenadine achieved statistical significance in reducing itch scores. Fexofenadine also had the lowest rate of adverse reactions among the medications studied.

Are these antihistamines safe to use?

The study found no significant differences in side effects between any of the 10 drugs and a placebo. Fexofenadine was noted for having the lowest rate of adverse reactions. You should talk to your doctor to determine which medication is safest and best for your specific needs.

Study Details

Study typeMeta analysis

EvidenceLevel 1

PublishedAug 2026

View Original Abstract ↓

To evaluate the efficacy and safety of 10 commonly used second-generation H1 antihistamines (cetirizine, levocetirizine, loratadine, desloratadine, ebastine, bilastine, olopatadine, rupatadine, fexofenadine, and mizolastine) at licensed doses in treating chronic urticaria using network meta-analysis. Seven electronic databases were searched, including PubMed, Embase, Web of Science, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang Data Knowledge Service Platform, and Chinese Biomedical Literature Service System. Relevant literature from inception to the end of December 2025 was retrieved. Studies meeting the criteria were selected, and network meta-analysis was performed using Stata 16 software. A total of 54 studies involving 7,290 patients were included. Network meta-analysis indicated that olopatadine, mizolastine, bilastine, and levocetirizine were more effective than placebo in improving total symptom scores. All 10 drugs were superior to placebo in reducing itching scores, although only fexofenadine achieved statistical significance. For reducing wheal scores, ebastine was significantly more effective than mizolastine and loratadine. Regarding adverse reactions, no significant differences were observed between any of the drugs and placebo, with fexofenadine having the lowest adverse reaction rate. Sensitivity analyses excluding highrisk studies confirmed the robustness of findings across all outcomes. Based on current evidence, olopatadine at licensed dose exhibited the best efficacy in reducing total symptom scores. Fexofenadine was most effective for improving itching scores and ebastine was optimal for reducing wheal scores. In addition, fexofenadine had the lowest incidence of adverse reactions. However, the conclusions of this study still need to be validated by further high-quality randomized controlled trials.

Olopatadine and mizolastine are more effective than placebo for total symptom scores in chronic urticariaSpecific Antihistamines Show Different Success Rates for Chronic Urticaria

How this fits prior evidence

Common questions

Study Details

First-line immune checkpoint inhibitor combinations improve overall survival in extensive-stage small-cell lung cancer

Immune checkpoint inhibitors combined with chemotherapy improve small cell lung cancer survival

Clinical research that matters. Delivered to your inbox.

Olopatadine and mizolastine are more effective than placebo for total symptom scores in chronic urticariaSpecific Antihistamines Show Different Success Rates for Chronic Urticaria

How this fits prior evidence

Common questions

More on Chronic Urticaria

Study Details

First-line immune checkpoint inhibitor combinations improve overall survival in extensive-stage small-cell lung cancer

Immune checkpoint inhibitors combined with chemotherapy improve small cell lung cancer survival

Clinical research that matters. Delivered to your inbox.

Related in Oncology

From Other Specialties